Vas Narasimhan, Novartis CEO (Thibault Camus/AP Images, Pool)

In the mid­dle of an R&D shake­up, No­var­tis makes a $300M in­vest­ment in ear­ly-stage bi­o­log­ics re­search tech

With­in the past six months, No­var­tis has tapped new lead­ers for both its re­search arm and de­vel­op­ment or­ga­ni­za­tion. But Vas Narasimhan isn’t done re­vamp­ing the glob­al R&D org.

While his pre­vi­ous moves in­volved big cuts, this time the CEO is look­ing to add some­thing: a $300 mil­lion ini­tia­tive to bol­ster No­var­tis’ ca­pac­i­ty and ca­pa­bil­i­ties for “ear­ly tech­ni­cal de­vel­op­ment of bi­o­log­ics.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.